Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8441795 | European Journal of Cancer | 2015 | 10 Pages |
Abstract
RRM1 appeared to be a promising target for gene therapy, and Ad-shRRM1 had strong antitumour effects, specifically anti-proliferative and pro-apoptotic effects, against NSCLC cells that overexpressed RRM1. Combination therapy with Ad-shRRM1 and GEM may become a new treatment option for patients with NSCLC.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Yoshimasa Tokunaga, Dage Liu, Jun Nakano, Xia Zhang, Kazuhito Nii, Tetsuhiko Go, Cheng-long Huang, Hiroyasu Yokomise,